Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | TDO2 | P48775 | 2/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.44 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | DAO | P14920 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.34 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12052163 | 1.00 | IDO1 (0.44) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL8256061 | 1.00 | IDO1 (0.44) | IDO1TDO2AOC3MAOAMAOB | |
| Hydrochloric Acid SCHEMBL25383097 | 0.98 | IDO1 (0.46) | IDO1TDO2AOC3MAOAMAOB | |
| Hydrochloric Acid SCHEMBL25383101 | 0.98 | IDO1 (0.46) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL3271282 | 0.87 | DPP4 (0.45) | DPP4ADRB2HTT | |
| SCHEMBL3252261 | 0.84 | IDO1 (0.52) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL2008053 | 0.84 | IDO1 (0.52) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL12568800 | 0.84 | IDO1 (0.52) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL9906118 | 0.84 | IDO1 (0.52) | IDO1TDO2AOC3MAOAMAOB | |
| SCHEMBL7267227 | 0.83 | IDO1 (0.43) | IDO1TDO2AOC3MAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101704756-A | Synthesis method of 1- (4-fluorophenyl) -2-methyl-2-propylamine | DALIAN KAIFEI FINE CHEMICALS C | 2010-05-12 | — | — | CN | claimed |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | BAYER AKTIENGESELLSCHAFT (DE) | 2026-01-27 | — | — | US | disclosed |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | BAYER AKTIENGESELLSCHAFT (DE) | 2025-12-23 | — | — | US | disclosed |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2025-07-29 | — | — | US | disclosed |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | EIKONIZO THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | US | disclosed |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | EIKONIZO THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 2023-09-21 | — | — | US | disclosed |
| US-20230064576-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-03-02 | — | — | US | disclosed |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | ABBOTT LABORATORIES | 2004-06-24 | — | — | US | disclosed |
| US-20040106559-A1 | Hepatitis C virus inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-03 | — | — | US | disclosed |
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | BRISTOL-MYERS SQUIBB COMPANY | 2004-03-18 | — | — | US | disclosed |
| WO-2003059269-A2 | ACRIDONE INHIBITORS OF IMPDH ENZYME | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-07-24 | — | — | WO | disclosed |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2003-02-20 | — | — | US | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | AMERICAN HOME PRODUCTS CORPORATION | 2002-02-28 | — | — | US | disclosed |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | AMERICAN HOME PRODUCTS CORPORATION (US) | 2001-11-08 | — | — | US | disclosed |
| CN-1285820-A | Metabotropic glutamate receptor antagonists for the treatment of central nervous system disorders | NPS PHARMA INC (US) | 2001-02-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053955-A1 | Acridone inhibitors of IMPDH enzyme | IMPDH2, IMPDH1, XDH | IDO1 255/4885TDO2 160/4885AOC3 66/4885 |
| US-20240307391-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC1, HDAC2 | IDO1 2471/4885TDO2 3690/4885AOC3 1916/4885 |
| US-20040121964-A1 | Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) | DPP4, DPP3, DPP7 | IDO1 454/4885TDO2 3280/4885AOC3 4096/4885 |
| US-20230064576-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | PNPO, PDXK, BLVRB | IDO1 379/4885TDO2 207/4885AOC3 516/4885 |
| US-20030036653-A1 | Diaminopyridine-containing thiourea inhibitors of herpes viruses | HAVCR2, CCR6, CXCR6 | IDO1 2099/4885TDO2 1407/4885AOC3 2186/4885 |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | IDO1 4095/4885TDO2 4202/4885AOC3 2460/4885 |
| US-20230295138-A1 | HETEROCYCLYL PYRIDINES AS NOVEL FUNGICIDES | PNPO, CBR3, HPD | IDO1 577/4885TDO2 177/4885AOC3 434/4885 |
| US-20010039348-A1 | Alpha-methylbenzyl-containing thiourea inhibitors of herpes viruses containing a phenylenediamine group | CCR6, HAVCR2, BCOR | IDO1 1875/4885TDO2 1387/4885AOC3 934/4885 |
| US-20020026055-A1 | Aminopyridine-containing thiourea inhibitors of herpes viruses | TK1, TPMT, CXCR6 | IDO1 2062/4885TDO2 2047/4885AOC3 2534/4885 |
| US-20260124204-A1 | METALLOENZYME INHIBITOR COMPOUNDS | HDAC6, HDAC3, HDAC1 | IDO1 2887/4885TDO2 1856/4885AOC3 860/4885 |
| US-11938134-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | IDO1 2471/4885TDO2 3690/4885AOC3 1916/4885 |
| US-20040106559-A1 | Hepatitis C virus inhibitors | HAVCR2, HCCS, RNASE1 | IDO1 970/4885TDO2 3519/4885AOC3 656/4885 |
| US-12501900-B2 | Heterocyclyl pyridazine as fungicidal compounds | PNPO, PDXK, BLVRB | IDO1 379/4885TDO2 207/4885AOC3 516/4885 |
| US-20260137083-A1 | HETEROCYCLYL PYRIDAZINE AS FUNGICIDAL COMPOUNDS | CBR1, CBR3, CYC1 | IDO1 234/4885TDO2 127/4885AOC3 7/4885 |
| US-12534456-B2 | Heterocyclyl pyridines as novel fungicides | CBR1, CBR3, NOX1 | IDO1 315/4885TDO2 155/4885AOC3 21/4885 |
| US-12370194-B2 | Metalloenzyme inhibitor compounds | HDAC6, HDAC1, HDAC2 | IDO1 2471/4885TDO2 3690/4885AOC3 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.